|
Sign In to gain access to subscriptions and/or personal tools.
|
Treating resistant hypertension in type 2 diabetes: a role for spironolactone?
Adrian G Stanley
Department of Cardiovascular Sciences, University of Leicester, Robert Kilpatrick Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK, as90{at}le.ac.uk
Philip Swales
Department of Cardiovascular Sciences, University of Leicester, Robert Kilpatrick Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK
Herbert Thurston
Department of Cardiovascular Sciences, University of Leicester, Robert Kilpatrick Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK
Bryan Williams
Department of Cardiovascular Sciences, University of Leicester, Robert Kilpatrick Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK
References
- Anon. Spironolactone: No longer for hypertension. Drug Ther Bull 1988;26:88.[CrossRef][Medline]
[Order article via Infotrieve]
- Johnston LC, Grieble HG Treatment of arterial hypertensive disease with diuretics. V. Spironolactone, an aldosterone antagonist. Arch Intern Med 1967;119:225-31.[Abstract/Free Full Text]
- Clement DL Effect of spironolactone on systemic blood pressure, limb blood flow and response to sympathetic stimulation in hypertensive patients. Eur J Clin Pharmacol 1992;21:263-7.[CrossRef]
- Henry M., Wehrlen M., Pelletier, Capron MH Spironolactone versus nifedipine in essential hypertension. Am J Cardiol 1990;65:36K-38K.[CrossRef][Medline]
[Order article via Infotrieve]
- Schohn DC, Spiesser R., Wehrlen M., Pelletier, Capron MH Aldactazine/captopril combination, safe and effective in mild to moderate systemic hypertension: report on a multicenter study of 967 patients. Am J Cardiol 1990;65:4K-6K.[CrossRef][Medline]
[Order article via Infotrieve]
- Williams B., Poulter NR, Brown MJ et al. British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ouzan J., Pérault C., Lincoff M., Carré E., Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002;15:333-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Brilla CG, Matsubara LS, Weber KT Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A-16A.[CrossRef][Medline]
[Order article via Infotrieve]
- Falch DK, Schreiner A. The Effect of Spironolactone on Lipid, Glucose and Uric Acid Levels in Blood during Long-Term Administration to Hypertensives. Acta Med Scand 1983;213:27-30.[Web of Science][Medline]
[Order article via Infotrieve]
- Juurlink DN, Mamdani MM, Lee DS et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.[Abstract/Free Full Text]
- Winer BM, Lubbe WF, Colton T. Antihypertensive actions of diuretics. Comparative study of an aldosterone antagonist and a thiazide, alone and together. JAMA 1968;204:775-9.[Abstract/Free Full Text]
- Large DM, Carr PH, Laing I., Davies M. Hyperkalaemia in diabetes mellitus - potential hazards of coexisting hyporeninaemic hypoaldosteronism. Postgrad Med J 1984;60:370-3.[Abstract/Free Full Text]
The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 2,
90-92 (2006)
DOI: 10.1177/14746514060060020701
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Chapman, J. Dobson, S. Wilson, B. Dahlof, P. S. Sever, H. Wedel, N. R. Poulter, and on behalf of the Anglo-Scandinavian Cardiac Outcom
Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension
Hypertension,
April 1, 2007;
49(4):
839 - 845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Goodfriend
Treating Resistant Hypertension With a Neglected Old Drug
Hypertension,
April 1, 2007;
49(4):
763 - 764.
[Full Text]
[PDF]
|
|
|
|
|
